<DOC>
	<DOC>NCT02145676</DOC>
	<brief_summary>This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.</brief_summary>
	<brief_title>OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Upper limb spasticity in the elbow and shoulder due to stroke, with the most recent stroke at least 3 months ago Spasticity in the nonstudy upper limb that requires treatment Presence of fixed contractures in of the study muscles in elbow or shoulder Profound atrophy of muscles to be injected Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or constraintinduced movement therapy (CIMT) for the study limb within 3 months Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1 month Condition other than stroke contributing to upper limb spasticity Diagnosis of myasthenia gravis, EatonLambert syndrome, and/or amyotrophic lateral sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>